Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
AMICUS THERAPEUTICS, INC. (FOLD)
|
Add to portfolio |
|
|
|
| Price: |
$12.11
| | Metrics |
| OS: |
287.1
|
M
| |
-166
|
% ROE
|
| Market cap: |
$3.48
|
B
| |
-84
|
% ROIC
|
|
Net debt:
|
$128
|
M
| |
|
|
|
EV:
|
$3.6
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($129)
|
M
| |
|
|
| EPS |
($0.64)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 329.2 | 305.5 | 260.9 | 182.2 | 91.2 | 36.9 | 5.0 | 0.0 |
| Revenue growth | 7.8% | 17.1% | 43.2% | 99.7% | 147.1% | 644.9% | | -100.0% |
| Cost of goods sold | 38.6 | 34.5 | 31.0 | 22.0 | 14.4 | 6.2 | 0.8 | 0.0 |
| Gross profit | 290.6 | 271.0 | 229.8 | 160.3 | 76.8 | 30.7 | 4.1 | 0.0 |
| Gross margin | 88.3% | 88.7% | 88.1% | 87.9% | 84.2% | 83.1% | 83.2% | |
| Selling, general and administrative | 213.0 | 192.7 | 156.4 | 169.9 | 127.2 | 88.7 | 71.2 | 47.3 |
| Research and development | 276.7 | 272.0 | 308.4 | 286.4 | 270.9 | 149.3 | 104.8 | 76.9 |
| EBIT | -204.4 | -199.9 | -243.9 | -300.7 | -325.5 | -210.9 | -175.1 | -126.0 |
| EBIT margin | -62.1% | -65.4% | -93.5% | -165.0% | -356.7% | -571.0% | -3530.9% | |
| Pre-tax income | -242.0 | -241.6 | -274.3 | -355.9 | -349.1 | -449.1 | -203.8 | -132.1 |
| Income taxes | -5.5 | 8.9 | 2.6 | 0.5 | -0.1 | -165.1 | -3.7 | 0.0 |
| Tax rate | 2.3% | | | | 0.0% | 36.8% | 1.8% | 0.0% |
| Net income | -236.6 | -250.5 | -276.9 | -356.4 | -349.0 | -284.0 | -200.0 | -132.1 |
| Net margin | -71.9% | -82.0% | -106.1% | -195.6% | -382.5% | -769.0% | -4034.7% | |
| |
| Diluted EPS | ($0.82) | ($0.92) | ($1.07) | ($1.48) | ($1.88) | ($1.85) | ($1.49) | ($1.20) |
| Shares outstanding (diluted) | 289.1 | 271.4 | 258.9 | 240.4 | 185.8 | 153.4 | 134.4 | 109.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|